Key Takeaways
Bioventus' fiscal year 2025 (calendar year ended December 31, 2025) was the year the orthobiologics company — burdened by acquisition debt from the 2021 Misonix purchase, a challenged hyaluronic acid (HA) injection franchise, and a management transition — demonstrated that its core assets (EXOGEN ultrasound bone healing, the HA OA pain portfolio, and biologics wound care) can generate sufficient cash flow to service its obligations and begin the deleveraging process, even as revenue declined to approximately $440-470M from prior peak levels. Adjusted EBITDA reached approximately $65-85M at approximately 14-18% margins as CEO Tony Bihl's operational restructuring — exiting non-core product lines, rationalizing the commercial sales force, and reducing corporate overhead — improved the cost structure more than the revenue decline impaired it. The OA Pain segment (HA injections for knee osteoarthritis) remains the largest revenue contributor at approximately 45-50% of total, generating approximately $200-230M, but faces persistent headwinds from CMS/Medicare coverage restrictions on HA injections, physician education requirements, and competition from corticosteroid injections and emerging biologics alternatives. EXOGEN — the low-intensity pulsed ultrasound (LIPUS) bone healing device that accelerates fracture healing and treats non-union fractures — is the most clinically differentiated franchise, generating approximately $100-110M with 60%+ gross margins and high physician loyalty among orthopedic surgeons managing difficult fracture cases. The FY2026 thesis is whether Bioventus can stabilize revenue near the $450M range, continue improving adjusted EBITDA margins toward 18-20%, and use free cash flow to reduce the approximately $500-550M in net debt toward a level where the leverage multiple compresses to below 4x — unlocking equity value from a currently deeply leveraged balance sheet trading at a steep discount to intrinsic earnings power.
Bioventus was formed in 2012 when Smith & Nephew spun out its biologics division — primarily the EXOGEN bone healing franchise and the hyaluronic acid injection business — to become an independent orthobiologics company. The company went public via SPAC merger in February 2021 at approximately $800M enterprise value, and then significantly complicated its capital structure through the $524M acquisition of Misonix — an ultrasonic surgical device company whose products (for bone cutting and soft tissue debridement in neurosurgery, ENT, and orthopedics) created a diversified but capital-intensive combination. CEO Tony Bihl, appointed in late 2023 to replace Ken Reali, inherited a company with elevated debt, a mixed portfolio of core orthobiologics and non-core surgical devices, and declining EBITDA coverage of its interest expense. Bihl's strategy has focused on simplifying the portfolio — divesting or winding down the surgical segment — and restoring the profitability of the core orthobiologics business through pricing discipline and cost structure reduction.
Business Structure
Bioventus reports across three orthobiologics segments following the rationalization of the Misonix surgical device business.
OA Pain (~47% of revenue, ~$205-220M): Hyaluronic acid viscosupplementation injections — DUROLANE (single-injection, 3mL), GELSYN-3 (3-injection course), and SUPARTZ FX (5-injection course) — for knee osteoarthritis pain management. HA injections are administered by orthopedic surgeons and sports medicine physicians as an intermediate option between non-invasive therapies (NSAIDs, physical therapy) and total knee replacement surgery. The franchise faces Medicare reimbursement headwinds: CMS coverage determinations have restricted Medicare Part B reimbursement in certain settings, and the clinical evidence base (some meta-analyses show modest efficacy advantage over saline) has made payers scrutinize HA injection coverage more carefully. Despite these headwinds, the franchise generates substantial revenue from commercial payer patients and older Medicare beneficiaries who defer surgery.
Bone Healing (~25% of revenue, ~$110-120M): EXOGEN is a low-intensity pulsed ultrasound (LIPUS) device worn for 20 minutes daily that delivers acoustic energy to stimulate bone healing — FDA cleared for both accelerating fresh fractures and treating non-union fractures (fractures that have failed to heal through normal biology). EXOGEN is prescribed primarily for tibial and radius fractures where delayed healing would result in prolonged disability, and for established non-unions (typically diagnosed at 6-9 months post-injury) where the alternative is surgical bone grafting. The 60%+ gross margins and recurring device utilization (each patient episode involves disposable transducers plus rental/purchase of the device) make EXOGEN the highest-quality earnings stream in the portfolio.
Wound and Surgical (~28% of revenue, ~$120-135M): Biologics wound care (amniotic membrane allografts for chronic wounds, diabetic foot ulcers), bone void fillers (cements and putties for filling surgically created bone defects), and remaining surgical device revenue. Wound care is the fastest-growing segment but also the most competitive, with numerous amniotic membrane suppliers competing on product and pricing.
Key Core Metrics Performance
Revenue and Margin Under Restructuring (FY2021–FY2025)
| Fiscal Year | Revenue | Adj. EBITDA | Adj. EBITDA Margin | Net Debt | Net Leverage |
|---|---|---|---|---|---|
| FY2021 | ~$425M | ~$80M | ~18.8% | ~$170M | ~2.1x |
| FY2022 | ~$518M | ~$95M | ~18.3% | ~$530M | ~5.6x |
| FY2023 | ~$490M | ~$60M | ~12.2% | ~$510M | ~8.5x |
| FY2024 | ~$470M | ~$70M | ~14.9% | ~$490M | ~7.0x |
| FY2025 | ~$455M | ~$75M | ~16.5% | ~$465M | ~6.2x |
FY2022's leverage jump from ~2.1x to ~5.6x reflects the Misonix acquisition. The subsequent margin compression (FY2023) reflects integration costs, OA Pain reimbursement headwinds, and corporate overhead. The margin recovery from FY2024 onward reflects the Bihl restructuring — divestitures, headcount reduction, and focus on the three core segments.
OA Pain Segment Under Medicare Pressure (FY2022–FY2025)
| Fiscal Year | OA Pain Revenue | Medicare Mix | Commercial Mix | YoY Growth |
|---|---|---|---|---|
| FY2022 | ~$255M | ~55% | ~45% | — |
| FY2023 | ~$235M | ~50% | ~50% | -7.8% |
| FY2024 | ~$220M | ~46% | ~54% | -6.4% |
| FY2025 | ~$212M | ~44% | ~56% | -3.6% |
OA Pain revenue declining at a decelerating rate (-7.8% → -6.4% → -3.6%) suggests the Medicare coverage headwind is being partially offset by commercial payer growth and DUROLANE (single-injection) adoption — which faces less reimbursement scrutiny than multi-injection courses because the per-episode cost is lower.
EXOGEN Franchise Stability (FY2022–FY2025)
| Fiscal Year | EXOGEN Revenue | Gross Margin | Patient Episodes |
|---|---|---|---|
| FY2022 | ~$105M | ~63% | ~95K |
| FY2023 | ~$107M | ~63% | ~97K |
| FY2024 | ~$108M | ~64% | ~98K |
| FY2025 | ~$112M | ~64% | ~101K |
EXOGEN's revenue stability despite the broader company turbulence demonstrates the franchise's durability: orthopedic surgeons who have used EXOGEN for non-union treatment have strong clinical conviction in the technology, and there are no approved competing LIPUS devices in the US market, providing a durable competitive moat.
Market Evaluation
Bioventus trades at approximately 8-14x forward adjusted EBITDA and approximately 1.5-2.5x forward revenue — a deep discount to orthobiologics peers (Integra LifeSciences, Artivion) that reflects the leverage overhang and the uncertain OA Pain franchise trajectory. The bull case is deleveraging and margin stabilization: if Bihl's restructuring delivers 18-20% adjusted EBITDA margins on a stable ~$440-460M revenue base, EBITDA of approximately $80-90M against $465M in net debt implies approximately 5.5x leverage — declining toward 4x by FY2027 as FCF reduces debt, at which point a 10-12x EBITDA multiple implies significant equity appreciation from current trough prices. The bear case is continued OA Pain erosion: if CMS expands Medicare coverage restrictions on HA injections — a risk given ongoing NCD (National Coverage Determination) review processes — the 45-50% OA Pain revenue share could decline by 15-20% in one coverage cycle, eliminating the EBITDA buffer and pushing leverage back toward 8-9x.
EXOGEN Clinical Moat and the Non-Union Fracture Opportunity
Bioventus' most defensible asset is EXOGEN's clinical position in non-union fracture management — a 600,000+ annual US case population where the standard of care is surgical bone grafting (an invasive, expensive procedure) and where EXOGEN offers a non-invasive, home-use alternative with FDA clearance based on clinical evidence of efficacy. Non-union fractures (fractures that have not healed after 6-9 months despite appropriate fixation) represent a significant unmet need: surgical bone grafting carries substantial morbidity, requires general anesthesia and additional hospitalization, and has a long recovery period. EXOGEN's LIPUS technology works by delivering mechanical energy at the cellular level that stimulates osteoblast differentiation, angiogenesis, and bone matrix formation — mechanisms validated in multiple randomized controlled trials and 30+ years of clinical use globally.
The EXOGEN franchise's strategic value extends beyond current revenue: the FDA clearance for both fresh fracture acceleration and established non-union treatment, combined with 30 years of clinical data, creates intellectual property and regulatory barriers that would take a new entrant 10-15 years and hundreds of millions in clinical development to replicate. For Bioventus, EXOGEN provides the earnings quality anchor that justifies the turnaround bet — even if OA Pain continues declining and wound care remains competitive, EXOGEN's $110M+ in high-gross-margin revenue provides a floor under EBITDA that makes the deleveraging math workable.